Antares Pharma, Inc. (NASDAQ:ATRS)’s share price was up 5% during trading on Thursday . The company traded as high as $2.30 and last traded at $2.29. Approximately 1,084,703 shares traded hands during trading, a decline of 2% from the average daily volume of 1,105,100 shares. The stock had previously closed at $2.18.

A number of equities analysts recently commented on ATRS shares. ValuEngine downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright reiterated a “buy” rating and set a $3.50 price objective on shares of Antares Pharma in a research report on Wednesday, November 8th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, Piper Jaffray Companies set a $3.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $3.84.

The firm has a market capitalization of $356.61, a PE ratio of -20.73 and a beta of 0.25. The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. The business’s revenue was up 11.9% on a year-over-year basis. equities research analysts expect that Antares Pharma, Inc. will post -0.11 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. California Public Employees Retirement System raised its position in Antares Pharma by 4.1% in the third quarter. California Public Employees Retirement System now owns 972,694 shares of the specialty pharmaceutical company’s stock valued at $3,152,000 after purchasing an additional 38,394 shares during the period. Perceptive Advisors LLC raised its position in Antares Pharma by 2.0% in the third quarter. Perceptive Advisors LLC now owns 4,353,897 shares of the specialty pharmaceutical company’s stock valued at $14,107,000 after purchasing an additional 86,644 shares during the period. Schwab Charles Investment Management Inc. raised its position in Antares Pharma by 5.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 560,936 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after purchasing an additional 27,360 shares during the period. Wells Fargo & Company MN raised its position in Antares Pharma by 28.3% in the third quarter. Wells Fargo & Company MN now owns 1,335,906 shares of the specialty pharmaceutical company’s stock valued at $4,328,000 after purchasing an additional 294,810 shares during the period. Finally, First Eagle Investment Management LLC raised its position in Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after purchasing an additional 30,000 shares during the period. Institutional investors own 34.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Antares Pharma (ATRS) Trading Up 5%” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/13/antares-pharma-atrs-trading-up-5.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.